IntelligenceOverview
NewsBriefingJournalismTesseract
ExposureReportsNeural WebPlayersGeopoliticsSignal Map
MarketsMarket SignalsPulse
Entity

Cytokinetics

Cytokinetics is a biopharmaceutical company that develops small molecule drugs to treat diseases characterized by impaired muscle function, such as heart failure and amyotrophic lateral sclerosis (ALS).

Why it’s in the news: It is in the news because its lead drug candidate, omecamtiv mecarbil, achieved a positive outcome in a late-stage clinical trial, a key step toward potential regulatory approval.

Explore Cytokinetics in the interactive graph

Latest on Cytokinetics

  • STAT+: Cytokinetics details trial win for what could be its next approval
  • 13F: Deeter Investments Llp holds Cytokinetics ($6M)

Connections

4 entities linked to Cytokinetics across the news graph.

Also connected to (4)
Deeter Investments LlpSTAT+: Cytokinetics details trial win for what could be its next approvalSTATSEC
Open the interactive Neural Web →Intelligence Briefs